Company profile
VERU INC.
NASDAQ:VERUBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SABIZABULIN | phase3 | — | 6 | completed, terminated, withdrawn |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04388826 | phase2 | completed | 2020-06-18 | 2020-12-18 | Veru Inc. | COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111 |
| NCT06282458 | phase2 | completed | 2024-04-29 | 2025-04-11 | Veru Inc. | Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt |
| NCT05065411 | phase3 | terminated | 2022-04-11 | 2023-10-19 | Veru Inc. | Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer |
| NCT04869943 | phase3 | terminated | 2021-10-12 | 2024-01-09 | Veru Inc. | Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer |
| NCT05079360 | phase2 | withdrawn | 2023-03-15 | 2024-03-30 | Veru Inc. | Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer |
FDA applications (0)
No records yet.